会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHODS FOR PREDICTING ESOPHAGEAL ADENOCARCINOMA (EAC)
    • 预防食管腺癌(EAC)的方法
    • US20120053066A1
    • 2012-03-01
    • US12918438
    • 2009-02-19
    • Stephen J. MeltzerYulan ChengZhe Jin
    • Stephen J. MeltzerYulan ChengZhe Jin
    • C40B30/00C12Q1/68
    • C12Q1/6886C12Q2600/154C12Q2600/156
    • This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).
    • 本发明涉及例如用于预测受试者发生食管腺癌(EAC)或高度发育不良(HGD)的风险的方法,其包括在受试者的样品中测定各种组合的转录启动子区域的甲基化水平,其中 其他基因,(a)钙粘蛋白13,H钙粘蛋白(心脏)(CDH13); (b)速激肽-1(TAC1); (c)nel样1(NELL1); (d)α-激酶锚定蛋白12(AKAP12); (e)生长抑素(SST); (f)具有EGF样的跨膜蛋白和两个卵泡抑素样结构域(HPP1); (g)CDKN2a,细胞周期蛋白依赖性激酶抑制剂2a(p16); 或(h)休克相关转录因子3(RUNX3)。
    • 3. 发明授权
    • Small peptides specifically bind to colorectal cancers
    • 小肽特异性结合结肠直肠癌
    • US08435490B2
    • 2013-05-07
    • US12664302
    • 2008-06-04
    • John Martin AbrahamStephen J. Meltzer
    • John Martin AbrahamStephen J. Meltzer
    • A61K51/00A61M36/14
    • A61K51/08C12Q1/485G01N33/60
    • Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.
    • 在不同恶性肿瘤中存在的突变的频率和类型方面,癌症是非常不均匀的。 因此,对于所有患者来说,统一的临床治疗可能不是最佳的,个体化治疗方案的发展可能是有益的。 多个独特的小肽结合来自不同结肠腺癌的细胞系。 在接触两小时后,结肠直肠癌细胞能够将32P放射性同位素从小肽转移到细胞蛋白质; 转移发生在比结肠直肠癌细胞中显着更高的速率,而不是来源于其他癌症或来自正常组织的细胞系。